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Case Report: PTHrP Related Hypercalcemia in
Diffuse Large B-cell Lymphoma
Ankita Mehta, MD, and Evan Caruso, MD

INTRODUCTION

DISCUSSION

Hypercalcemia is commonly associated with solid tumor
malignancies, but less often with hematologic malignancies.
When present in hematologic malignancies, hypercalcemia
is often secondary to overproduction of Vitamin D from the
tumor cells. Very few cases with parathyroid hormone
related peptide (PTHrP) induced hypercalcemia in B-cell
lymphomas have been reported. Here we present a 44 year
old male with a history of chronic lymphoctic leukemia
who presented with hypercalcemia and an elevated PTHrP,
found to have a transformation to Diffuse Large B-cell
Lymphoma (DLBCL) .

Though hypercalcemia is commonly seen in adult T cell
lymphomas/leukemia and solid tumors via excess
production of PTHrP, less than 10% of patients with non
Hodgkins B-cell lymphomas develop hypercalcemia.2 The
hypercalcemia seen in B cell lymphomas is usually due to
non PTHrP related mechanisms. There are various
explanations of the pathophysiology for hypercalcemia in
hematologic malignancies. Most of the case studies that
have reported B-cell lymphomas with hypercalcemia
secondary to PTHrP hypersecretion are high grade
lymphomas. Our patient’s case supports these findings, as
he too had a Richter's transformation on bone marrow
biopsy.1 Correlation between the concentration of the
protein and the degree of hypercalcemia suggests a
causal relationship. Numerous case reports have shown
that hypercalcemia in B cell lymphoma is a poor prognostic
factor. In Majmudar's article, of the eight patients he
reported, median survival time from developing
hypercalcemia was nine months.3

CASE PRESENTATION
A 44 year old male with chronic lymphocytic leukemia
(CLL) status post four cycles of rituximab, cyclophosphamide, vincristine and prednisone and currently
undergoing treatment with ibrutinib presented with two
weeks of decreased appetite, fatigue, weakness, altered
mental status. Physical exam was only significant for mild
cervical lymphadenopathy. Labs revealed hypercalcemia
at 18.1 mg/dL, compared to 12 mg/dL one month prior to
admission. Work up of hypercalcemia revealed normal
intact PTH and Vitamin D levels, and elevated PTHrP at 57
pmol/L. Upon further investigation, including a bone
marrow biopsy, it was determined that the CLL had
transformed to a more aggressive subtype, diffuse large
B-cell Lymphoma. He did not complain of any abdominal
pain, but did complain of diffuse bone pain. CT of the
chest, abdomen, and pelvis showed adenopathy
throughout with some mild splenomegaly. The patient's
hypercalcemia was treated with fluids, calcitriol, and
pamidronate with improvement in symptoms and
normalization of calcium levels. His DLBCL was treated
with a cycle of cyclophosphamide, doxorubicin, vincristine,
and prednisone (CHOP). However, his neutrophil count
did not recover as expected and his calcium began to
increase again two weeks after initial treatment. A repeat
bone marrow biopsy was consistent with refractory B-cell
lymphoma. His hypercalcemia was again treated with
fluids and re-dosing of pamidronate, which stabilized his
calcium between 11 and 12 mg/dL, but did not normalize
it. He began experiencing fatigue and bone pain again. He
was started on dexamethasone 6 mg every 6 hours which
returned his calcium to normal range and relieved his
symptoms. His calcium has remained stable since, and he
is to undergo therapy with bendamustine, ofatumumab,
carboplatin, and etoposide.

KEY POINTS
The mechanisms of hypercalcemia in hematologic
malignancies are multifactorial and yet to be fully
understood. However, it is important to evaluate the cause
and promptly treat the hypercalcemia. It is imperative to
determine calcium levels given that it is a prognostic
indicator and of clinical significance. PTHrP mediated
hypercalcemia is rare in B cell lymphomas, but has been
reported in high grade and transformed disease and
should be considered in the evaluation of hypercalcemia
in this subset of patients.
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